NO20071142L - Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor - Google Patents

Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor

Info

Publication number
NO20071142L
NO20071142L NO20071142A NO20071142A NO20071142L NO 20071142 L NO20071142 L NO 20071142L NO 20071142 A NO20071142 A NO 20071142A NO 20071142 A NO20071142 A NO 20071142A NO 20071142 L NO20071142 L NO 20071142L
Authority
NO
Norway
Prior art keywords
renin inhibitor
methods
improved bioavailability
inhibitor
bioavailability
Prior art date
Application number
NO20071142A
Other languages
English (en)
Norwegian (no)
Inventor
Gian T Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071142(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20071142L publication Critical patent/NO20071142L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20071142A 2004-08-03 2007-02-28 Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor NO20071142L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03
PCT/EP2005/008369 WO2006013094A1 (fr) 2004-08-03 2005-08-02 Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine

Publications (1)

Publication Number Publication Date
NO20071142L true NO20071142L (no) 2007-04-26

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071142A NO20071142L (no) 2004-08-03 2007-02-28 Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor

Country Status (31)

Country Link
US (1) US7709532B2 (fr)
EP (2) EP2191823A1 (fr)
JP (1) JP5134366B2 (fr)
KR (1) KR20070040384A (fr)
CN (1) CN1993116B (fr)
AR (1) AR050043A1 (fr)
AT (1) ATE449601T1 (fr)
AU (1) AU2005268844B2 (fr)
BR (1) BRPI0514021A (fr)
CA (1) CA2572743C (fr)
CY (1) CY1109826T1 (fr)
DE (1) DE602005017905D1 (fr)
DK (1) DK1776099T3 (fr)
EC (1) ECSP077169A (fr)
ES (1) ES2335597T3 (fr)
HR (1) HRP20100064T1 (fr)
IL (1) IL180678A (fr)
MA (1) MA28821B1 (fr)
MX (1) MX2007001339A (fr)
MY (1) MY142180A (fr)
NO (1) NO20071142L (fr)
NZ (1) NZ552903A (fr)
PE (1) PE20060416A1 (fr)
PL (1) PL1776099T3 (fr)
PT (1) PT1776099E (fr)
RU (1) RU2404758C2 (fr)
SI (1) SI1776099T1 (fr)
TN (1) TNSN07038A1 (fr)
TW (1) TW200616610A (fr)
WO (1) WO2006013094A1 (fr)
ZA (1) ZA200610639B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (fr) * 2006-08-25 2008-02-27 Novartis AG Formulations galéniques de l'aliskiren
EP1927350A1 (fr) * 2006-11-24 2008-06-04 Novartis AG Procéde pour améliorer la biodisponibilite d'un inhibiteur de renine
WO2011012319A1 (fr) 2009-07-31 2011-02-03 Sandoz Ag Procede de preparation de ƒö-amino-alcaneamides et ω-amino-alcanethioamides
WO2012010651A2 (fr) 2010-07-23 2012-01-26 Sandoz Ag Procédé de préparation d'oméga-amino-alcaneamides et d'oméga-amino-alcanethioamides et intermédiaires de ce procédé
WO2014168255A1 (fr) * 2013-04-12 2014-10-16 国立大学法人京都大学 Accélérateur de la maturation de mégacaryocytes
WO2015035218A1 (fr) * 2013-09-05 2015-03-12 Howard University Procédé renforçant la biodisponibilité d'un médicament anti-vih
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0831870A4 (fr) 1995-06-07 1998-09-16 Avmax Inc Utilisation d'huiles essentielles pour accroitre la biodisponibilite des composes pharmaceutiques oraux
CO5251425A1 (es) * 1999-10-27 2003-02-28 Baker Norton Pharma Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
JP2003522152A (ja) * 2000-02-11 2003-07-22 プラエシス ファーマシューティカルズ インコーポレーテッド 薬物の生物学的利用能を高める方法
WO2001092468A2 (fr) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Nouvelles compositions pour l'expression du transporteur 1 d'histidine de peptide humain et leurs procedes d'utilisation
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
EP1465592A2 (fr) 2001-12-19 2004-10-13 Alza Corporation Preparation et forme posologique pour l'augmentation de la biodisponibilite buccale de macromolecules hydrophiles
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (fr) * 2002-05-03 2012-10-10 Hexal AG Formulation pharmaceutique stable contenant une statine combinee avec un inhibiteur de l'ace
US20050147629A1 (en) * 2002-06-28 2005-07-07 Jutta Riedl Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
TW200605867A (en) * 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds

Also Published As

Publication number Publication date
TNSN07038A1 (en) 2008-06-02
CN1993116B (zh) 2011-04-13
MX2007001339A (es) 2007-03-27
AR050043A1 (es) 2006-09-20
HRP20100064T1 (hr) 2010-03-31
CN1993116A (zh) 2007-07-04
JP5134366B2 (ja) 2013-01-30
EP1776099A1 (fr) 2007-04-25
PT1776099E (pt) 2010-01-06
IL180678A (en) 2011-04-28
IL180678A0 (en) 2008-03-20
WO2006013094A1 (fr) 2006-02-09
KR20070040384A (ko) 2007-04-16
ES2335597T3 (es) 2010-03-30
PE20060416A1 (es) 2006-06-09
US7709532B2 (en) 2010-05-04
CY1109826T1 (el) 2014-09-10
DE602005017905D1 (de) 2010-01-07
TW200616610A (en) 2006-06-01
PL1776099T3 (pl) 2010-05-31
RU2007107850A (ru) 2008-09-10
JP2008508340A (ja) 2008-03-21
MY142180A (en) 2010-10-15
EP2191823A1 (fr) 2010-06-02
AU2005268844A1 (en) 2006-02-09
ZA200610639B (en) 2008-05-28
MA28821B1 (fr) 2007-08-01
ATE449601T1 (de) 2009-12-15
NZ552903A (en) 2010-09-30
DK1776099T3 (da) 2010-03-01
SI1776099T1 (sl) 2010-03-31
EP1776099B1 (fr) 2009-11-25
CA2572743A1 (fr) 2006-02-09
CA2572743C (fr) 2012-12-04
AU2005268844B2 (en) 2009-03-05
RU2404758C2 (ru) 2010-11-27
BRPI0514021A (pt) 2008-05-27
ECSP077169A (es) 2007-02-28
US20080108703A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20071142L (no) Fremgangsmater for forbedret biotilgjengelighet av en renininhibitor
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
DK1258476T3 (da) Alfa-aminosyrederivater, fremgangsmåde til fremstilling heraf og deres anvendelse som dipeptidyl-peptidase-IV-inhibitorer (DDP IV)
NO20073650L (no) Stilbenderivater og deres anvendelse til binding og avbilding av amyloidplakker
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
BRPI0512193B8 (pt) composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
WO2006014665A3 (fr) Derives d'arylpyrrolidine servant d'antagonistes de nk-1/ssri
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
WO2006014664A3 (fr) Cyclopentylamine et derives de cyclohexylamine utilises comme antagonistes de nk-1/ssri
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
NO20084256L (no) DPP IV inhibitorformuleringer
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20050718L (no) Topikal behandling av hudsykdommer
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application